View all cases
UPC APP 8339/2025
—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Case details
- Status—ActionProcedural applicationCategoryOther Procedural
- Parties
- Respondents
- Amgen Technology (Ireland) Unlimited Company
- Amgen N.V.
- Amgen GmbH (DE)
- Amgen GmbH (AT)
- Amgen AB
- Amgen S.A.S.
- Amgen s.r.l.
- Amgen Biofarmacêutica Lda.
- Amgen Zdravila D.O.O.
Reps: Tilman Müller-Stoy (Bardehle Pagenberg) - Division
- Court of Appeal
- Judges
- —
- Technology
- Organic Chemistry
- Language
- —
- First decided
- Jun 19, 2025
Decisions
- 2025-06-19Appeal decisionGeneric application
The Court of Appeal set out general principles for rehearing applications under Art. 81(1)(b) UPCA, establishing that only fundamental procedural defects that would have led to a different outcome can justify rehearing, in proceedings where Alexion sought to reopen a dismissed provisional measures appeal against Amgen concerning EP 3 167 888.
Legal issues:Rehearing application (Art. 81(1) UPCA, R. 245 RoP)Fundamental procedural defectStandard for reopening final decisions
Documents
- 2AFD646F74F626C4549F4F2CC557128E_en.pdf2025-06-19EN